Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.21.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue:        
Grant and contract revenue $ 459,494 $ 593,165 $ 998,139 $ 1,495,045
Operating expenses:        
Research and development 4,216,294 2,790,797 7,622,542 5,573,303
General and administrative 2,853,265 1,801,674 7,620,910 5,072,222
Change in fair value of contingent consideration 105,000 843,000 111,000 816,000
Total operating expenses 7,174,559 5,435,471 15,354,452 11,461,525
Loss from operations (6,715,065) (4,842,306) (14,356,313) (9,966,480)
Change in fair value of warrant liability 4,679 (24,363) (4,023) (1,002,073)
Investor relations expense       (66,767)
Interest income 176,798 56,080 371,963 108,790
Other (expense) income, net (86,988) 273,771 (255,343) 16,292
Total non-operating income (loss) 94,489 305,488 112,597 (943,758)
Net loss before income taxes (6,620,576) (4,536,818) (14,243,716) (10,910,238)
Net loss (6,620,576) (4,536,818) (14,243,716) (10,910,238)
Net loss - non-controlling interest (77,379) (82,388) (168,341) (163,702)
Net loss attributable to Heat Biologics, Inc. $ (6,543,197) $ (4,454,430) $ (14,075,375) $ (10,746,536)
Net loss per share, basic and diluted $ (0.26) $ (0.35) $ (0.57) $ (1.04)
Weighted-average common shares outstanding, basic and diluted 25,137,466 12,561,549 24,671,281 10,372,352
Comprehensive loss:        
Net loss $ (6,620,576) $ (4,536,818) $ (14,243,716) $ (10,910,238)
Unrealized gain (loss) on foreign currency translation 26,661 (179,510) 44,929 39,294
Total comprehensive loss (6,593,915) (4,716,328) (14,198,787) (10,870,944)
Comprehensive loss attributable to non-controlling interest (77,379) (82,388) (168,341) (163,702)
Comprehensive loss - Heat Biologics, Inc. $ (6,516,536) $ (4,633,940) $ (14,030,446) $ (10,707,242)